Communiqués Agios Pharmaceuticals, Inc.

Actions

AGIO

US00847X1046

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:15:08 18/08/2026			Varia. 5j.	Varia. 1 janv.
34,68 ^USD	+3,14%		+6,00%	+27,30%

30/07	Transcript : Agios Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026
30/07	Agios Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

30/07	Agios Pharmaceuticals: Q2 Earnings Snapshot	AQ
30/07	Agios Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
21/07	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease	AQ
07/07	U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease	AQ
29/06	Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET	AQ
13/06	Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease	AQ
01/06	Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib	AQ
29/05	Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes	AQ
23/05	Agios, partenaire d’Avanzanite Bioscience, annonce l’autorisation de mise sur le marché de PYRUKYND® (mitapivat) dans l’Union européenne pour les adultes atteints de thalassémie	BU
22/05	Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia	BU
22/05	Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia	AQ
12/05	Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias	AQ
12/05	Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease	AQ
29/04	Agios Pharmaceuticals : 2025 Annual Report (15676d)	PU
29/04	Agios Pharmaceuticals : 2026 Proxy Statement (a7ac5c)	PU
29/04	Agios Pharmaceuticals : Q1 2026 Financial Results and Business Highlights	PU
29/04	Agios Pharmaceuticals: Q1 Earnings Snapshot	AQ
29/04	Agios Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
06/04	Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET	AQ
01/04	Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky	PR
31/03	AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money	PR
31/03	Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA	AQ
25/03	AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation	PR
18/03	ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation	PR
17/03	Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation	PR